

Healthcare Professional Survey to Assess the Effectiveness of Additional Risk Minimization Measures for Prescribing and Administration of Concentrated Insulin Human (Humulin R U-500 KwikPen) (B5K-MC-B012)

First published: 06/11/2017

Last updated: 08/11/2017

Study

Planned

Administrative details

EU PAS number

EUPAS21539

Study ID

21607

DARWIN EU® study

No

Study countries

☐ United States

Study description

This study aims to evaluate the impact of the Dear Health Care Provider Letter on prescriber understanding about the risk of hypoglycemia associated with Humulin R U-500 KwikPen and educational points to be emphasized in discussion with patients.

Study status

Planned

Research institutions and networks

Institutions

Covance

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Ayad Ali ali_ayad@lilly.com

Study contact

ali_ayad@lilly.com

Primary lead investigator

Ayad Ali

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 30/11/2016

Study start date

Planned: 31/07/2017

Date of final study report

Planned: 31/10/2017

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Eli Lilly and Company

Study protocol

[B5K-MC-B012_EU_PAS_Registered.pdf](#)(1.06 MB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Main study objective:

The primary study objective is to evaluate the impact of the Dear Healthcare Professional letter on prescriber understanding about the risk of hypoglycemia associated with Humulin R U-500 KwikPen and educational points to be emphasized in discussion with patients.

Study Design

Non-interventional study design

Cross-sectional

Other

Non-interventional study design, other

Survey Design

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

INSULIN HUMAN

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

200

Study design details

Outcomes

The risk minimization tools will be considered effective if the majority of respondents demonstrate they are aware of the key risks communicated.

Data analysis plan

Data collected from the survey will be reported as descriptive statistics. Frequency distributions with 95% CIs will be calculated for respondent responses to all questions that address the survey objectives. In addition to the overall analysis, survey data will be analyzed to determine if there are any differences for HCPs and medical specialty.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Cross-Sectional Survey, involving primary data collection.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No